News

AstraZeneca Pharma India announced that Bhavana Agrawal, Executive Director and Chief Financial Officer (CFO) has resigned from the position of CFO (Key Managerial Personnel) of the company with effect from the close of business hours on 31 August 2026, pursuant to her appointment to a regional role within the AstraZeneca Group.

Astrazeneca Pharma India announced that the 47th Annual General Meeting(AGM) of the company will be held on 10 August 2026.

AstraZeneca Pharma India has appointed Praveen K Mittal, Director - Corporate Affairs, with effect from 06 July 2026

Astrazeneca Pharma India announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 36 per equity Share (i.e. 1800%) , subject to the approval of the shareholders.

Net profit of Astrazeneca Pharma India declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025.For the full year,net profit rose 62.02% to Rs 187.52 crore in the year ended March 2026 as against Rs 115.74 crore during the previous year ended March 2025. Sales rose 32.59% to Rs 2275.58 crore in the year ended March 2026 as against Rs 1716.29 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales578.61480.48 20 2275.581716.29 33 OPM %10.5317.98 -11.5114.80 - PBDT64.82101.84 -36 286.03293.14 -2 PBT59.2284.15 -30 257.45253.15 2 NP44.8858.25 -23 187.52115.74 62 Powered by Capital Market - Live News